Ranibizumab "Treat and Extend" in Diabetic Macular Edma

An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema

This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to diabetic macular edema.

Inclusion Criteria:

• Visual impairment due to focal or diffuse macular edema with center involvement
• Diabetes type 1 or 2, HbA1c < 12.0%
• CRT = or > 250 μm

Exclusion Criteria:

• Active inflammation or infection
• Uncontrolled glaucoma
• Iris neovascularization, active proliferative retinopathy or vitreomacular traction
• Prior laser photocoagulation according to defined timelines
• History of stroke, uncontrolled hypertension

Other protocol-defined inclusion/exclusion criteria may apply